Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain
Officers; Compensatory Arrangements of Certain Officers.
On March 29, 2021, Frank P. Muscolo, the controller and principal accounting officer of
Trevi Therapeutics, Inc. (the Company), and the Company agreed that, in connection with the hiring of Christopher Galletta to serve as the Companys controller, Mr. Muscolo would cease to serve as the Companys principal
accounting officer, effective upon April 12, 2021, Mr. Gallettas start date with the Company. Mr. Galletta was hired in anticipation of Mr. Muscolos planned retirement in early 2022. Mr. Muscolo will continue as
an employee of the Company until his retirement date.
Upon his start date of April 12, 2021, Mr. Galletta will serve as the Companys
principal accounting officer. Mr. Galletta, 43, served as Director of Financial Reporting at SS&C Technologies Holdings, Inc., a publicly-traded global financial services and software company, from July 2016 until March 2021, and as
Assistant Vice President, Corporate Accounting at Virtus Investment Partners, Inc., a publicly-traded investment management company, from October 2011 to July 2016. Previously, he held various roles at TransAct Technologies Incorporated, a
publicly-traded software and printing solutions company, including serving as Chief Accounting Officer and Corporate Controller from 2010 to 2011, as Corporate Controller from 2007 to 2010, and as Assistant Corporate Controller from 2005 to 2007.
Earlier in his career, Mr. Galletta was employed by PricewaterhouseCoopers LLP. Mr. Galletta received a Bachelor of Business Administration with a major in accounting from Hofstra Universitys Frank G. Zarb School of Business in 2000
and is a Certified Public Accountant licensed by the state of New York, although his license is currently inactive.
In connection with
Mr. Gallettas hiring, he will be granted an option to purchase 25,000 shares of the Companys common stock at an exercise price per share equal to the closing price of the Companys common stock on the date of grant. The option
will vest as to 25% of the shares underlying the option on the first anniversary of the grant date, and as to an additional 1/48th of the original number of shares underlying the option monthly thereafter. He will also enter into the
Companys standard form of indemnification agreement, a copy of which was filed as Exhibit 10.12 to the Companys Registration Statement on Form S-1 (File
No. 333-230745) filed with the SEC on April 5, 2019. Pursuant to the terms of this agreement, the Company may be required, among other things, to indemnify Mr. Galletta for some expenses,
including attorneys fees, judgments, fines and settlement amounts incurred by him in any action or proceeding arising out of his service to the Company.